DiaMedica Therapeutics Inc.

NasdaqCM:DMAC Stock Report

Market Cap: US$443.7m

DiaMedica Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:DMAC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 Nov 25BuyUS$944,538Jan StahlbergIndividual113,352US$8.57
25 Nov 25BuyUS$7,631,469Jan StahlbergIndividual1,061,277US$8.57
21 Nov 25BuyUS$1,547,574Jan StahlbergIndividual208,872US$7.41
20 Nov 25BuyUS$951,213Jan StahlbergIndividual128,426US$7.41
19 Nov 25BuyUS$1,732,361Jan StahlbergIndividual240,352US$7.21
18 Nov 25BuyUS$1,234,618Jan StahlbergIndividual182,882US$6.75
17 Nov 25BuyUS$1,221,165Jan StahlbergIndividual187,393US$6.52
27 Aug 25BuyUS$5,958,107Jan StahlbergIndividual1,000,000US$6.00
27 Aug 25BuyUS$662,477Jan StahlbergIndividual110,420US$6.00
22 Aug 25BuyUS$1,062,340Jan StahlbergIndividual179,067US$5.99
15 Aug 25BuyUS$2,207,253Jan StahlbergIndividual372,248US$6.00
23 Jul 25BuyUS$1,400,000Richard JacintoIndividual400,000US$3.50
23 Jul 25BuyUS$9,999,997Thomas von KochIndividual2,857,142US$3.50
23 Jul 25BuyUS$1,400,000Richard JacintoIndividual400,000US$3.50
23 Jul 25BuyUS$4,999,999Jan StahlbergIndividual1,428,571US$3.50
23 Jul 25BuyUS$9,999,997Thomas von KochIndividual2,857,142US$3.50
23 Jul 25BuyUS$5,400,000Jan StahlbergIndividual1,542,857US$3.50

Insider Trading Volume

Insider Buying: DMAC insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of DMAC?
Owner TypeNumber of SharesOwnership Percentage
Hedge Funds3,269,7616.28%
General Public10,798,75820.7%
Institutions12,677,82824.3%
Individual Insiders25,331,09248.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.8%.

Top Shareholders

Top 25 shareholders own 76.11% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.9%
Jan Stahlberg
8,825,742US$75.2m13.7%no data
16.1%
Thomas von Koch
8,383,577US$71.4m51.7%no data
9.52%
Richard Jacinto
4,958,823US$42.2m8.77%no data
6.28%
Omega Advisors, Inc.
3,269,761US$27.9m98.2%1.03%
4.7%
Leon Cooperman
2,450,000US$20.9m0%no data
4.17%
Dialectic Capital Management, LP
2,173,529US$18.5m0%50.58%
3.22%
BlackRock, Inc.
1,678,139US$14.3m40.8%no data
2.28%
Millennium Management LLC
1,187,309US$10.1m0%0.01%
1.68%
Paragon Associates, Ltd.
875,000US$7.5m34.6%11.95%
1.57%
Leon & Toby Cooperman Family Foundation
819,761US$7.0m0%100.0%
1.37%
Geode Capital Management, LLC
711,818US$6.1m13%no data
1.28%
The Vanguard Group, Inc.
664,575US$5.7m-56.7%no data
1.11%
Morgan Stanley
576,847US$4.9m144%no data
0.97%
First Manhattan Co. LLC
505,000US$4.3m-16.7%0.01%
0.92%
State Street Global Advisors, Inc.
476,583US$4.1m89.2%no data
0.73%
Bleichroeder LP
382,317US$3.3m0%0.58%
0.65%
R. Giuffre
339,893US$2.9m0%no data
0.65%
Northern Trust Global Investments
339,578US$2.9m4.63%no data
0.39%
LPL Financial LLC
203,150US$1.7m2.86%no data
0.35%
Osaic Wealth, Inc.
182,305US$1.6m26.4%no data
0.32%
Richard Pilnik
165,453US$1.4m0%no data
0.27%
Corient Private Wealth LLC
140,000US$1.2m0%no data
0.25%
Corient IA LLC
132,500US$1.1m0%0.83%
0.19%
Cantor Fitzgerald Asset Management
100,000US$852.0k0%0.01%
0.18%
Charles Schwab Investment Management, Inc.
92,427US$787.5k16.2%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/07 06:08
End of Day Share Price 2026/01/07 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DiaMedica Therapeutics Inc. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Kyle BauserColliers Securities
Chase KnickerbockerCraig-Hallum Capital Group LLC